Clinical and Radiological Improvement of Periodontal Disease in Patients With Type 2 Diabetes Mellitus Treated With Alendronate: A Randomized, Placebo‐Controlled Trial
Authors:
- Laura Eugenia NavaLNLaura Eugenia Nava
- Carlos Vázquez de la TorreCTCarlos Vázquez de la Torre
- Francisco Sánchez‐MarínFSFrancisco Sánchez‐Marín
- Ma. Eugenia Garay‐SevillaMGMa. Eugenia Garay‐Sevilla
- Juan Manuel MalacaraJMJuan Manuel Malacara
- 1 February 2001
- journal article
- clinical trial
- Published by Wiley in Journal of Periodontology
- Vol. 72 (2) , 204-209
Abstract
Background: Alendronate (ALN) is an aminobisphosphonate commonly used for osteoporosis in postmenopausal women. We studied the effect of ALN on bone loss prevention in type 2 diabetes mellitus patients with periodontal disease.Methods: In a controlled double‐blind, randomized study we evaluated prospectively diabetic patients paired by gender and years since diagnosis for 6 months. The study included 40 patients (20 men and 20 women), 50 to 60 years old, with more than 5 years since diagnosis of diabetes and established periodontitis. They were randomly allocated to alendronate (10 mg/daily) or placebo treatment for 6 months. The endpoints of treatment were: the distance between the alveolar bone border and the cemento‐enamel‐junction (CEJ) evaluated by means of digital radiographic imaging, a biochemical marker of bone resorption (urine N‐telopeptide) (Ntx), and periodontal parameters. Metabolic control was assessed at baseline and after 6 months.Results: Baseline and 6‐month glycated hemoglobin levels were similar in both groups. Alendronate induced a significant decrease in NTx at 6 months (P = 0.006). Periodontal parameters improved in both groups. However, they were significantly better for the ALN treated group. Alveolar bone border‐CEJ distance increased in the placebo, but decreased in the ALN group (P = 0.0003).Conclusions: In type‐2 diabetic patients, alendronate induced more improvement in alveolar bone crest height than control therapy. No differences in urinary N‐telopeptide or glycated hemoglobin were observed in this short‐term randomized controlled pilot trial. J Periodontol 2001;72:204‐209.Keywords
This publication has 18 references indexed in Scilit:
- Local Delivery of an Amino Bisphosphonate Prevents the Resorptive Phase of Alveolar Bone Following Mucoperiosteal Flap Surgery in RatsJournal of Periodontology, 1997
- Bisphosphonate therapy of reflex sympathetic dystrophy syndromeAnnals of the Rheumatic Diseases, 1997
- Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly WomenThe Journal of Clinical Endocrinology & Metabolism, 1997
- Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trialThe American Journal of Medicine, 1996
- Severe Periodontitis and Risk for Poor Glycemic Control in Patients with Non‐Insulin‐Dependent Diabetes MellitusJournal of Periodontology, 1996
- Alendronate Treatment of Naturally‐Occurring Periodontitis in Beagle DogsJournal of Periodontology, 1995
- Periodontal Disease in Non‐Insulin Dependent Diabetes Mellitus (NIDDM)Journal of Periodontology, 1994
- Preclinical pharmacology of alendronateOsteoporosis International, 1993
- Effects of a Bisphosphonate on Experimental Periodontitis in MonkeysJournal of Periodontology, 1992
- Altering the Progression of Human Alveolar Bone Loss With the Non‐Steroidal Anti‐Inflammatory Drug FlurbiprofenJournal of Periodontology, 1989